biomedical sciences research institute - Research - University of Ulster

More documents

Recommendations

Info

These areas are the subject of several national and international patents. Patents linked to stable GIP receptoragonists have been licensed to a major USA based pharmaceutical company through the spin-out company DiabeticaLtd. It is hoped that clinical studies will start shortly and ultimately lead to new agents for diabetes therapy which willhave a significant impact on the end users.Indicators of Research Esteem:Member of the Editorial Board of British Journal of Pharmacology (2005-2009)Member of the Editorial Board of Journal of Endocrinology (2004-2009)Member of committee for Irish Endocrine Society (2006-present)Member of HPSS R&D Office Clinical Research Fellowship Review Panel (2005-2007)Professor O’Harte is a co-founder with 4 other selected academic/clinical colleagues in the UK of a unique advancedtraining program entitled Innovators in Diabetes (IDia) for young research scientists and clinicians working in thediabetes field in the UK and N. Ireland (rolling program 2008-onwards). The inaugural meeting for this initiativesponsored by a Novo Nordisk education grant was held at the Barnsdale Lodge Hotel near Oakham, Rutland, UK for3 days (8-10 May 2008 inclusive) and will continue annually in May 2009 and thereafter.Publications:Alana I, Malthouse JP, O’Harte FPM and Hewage CM; The bioactive conformation of glucose-dependent insulinotropicpolypeptide by NMR and CD spectroscopy; Proteins: Structure, Function and Bioinformatics, 68: 92-99, 2007Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O’Harte FPM and Flatt PR; Effects of antidiabetic drugson dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity ofglucagons-like peptide-1; European Journal of Pharmacology, 568: 278-286, 2007Irwin N, McClean PL, Cassidy RS, O’Harte FPM, Green BD, Gault VA, Harriott P and Flatt PR; Comparison of the antidiabeticeffects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistantN-AcGIP and exendin(1-39)amide; Diabetes Metab. Research Reviews, 23: 572-579, 2007Irwin N, McClean PL, O’Harte FPM, Gault VA, Harriott P and Flatt PR; Early administration of the glucosedependentinsulinotropic polypeptide receptor antagonist (Pro 3 )GIP prevents the development ofdiabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice;Diabetologia, 50: 1532-1540, 2007McKillop AM, Duffy NA, Lindsay JR, O’Harte FPM, Bell PM and Flatt PR; Decreased dipeptidyl peptidase-IV activityand glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects; Diab. Res. Clin. Pract, 79: 79-85, 2008Dr NH McClenaghanHead of School of Biomedical SciencesContact details:T: +44 (0)28 70323011nh.mcclenaghan@ulster.ac.ukBrief profile:Conducted research at the University of Uppsala, Sweden (1991-92) before graduating with a BSc Hons and PhDfrom the University of Ulster. Research Fellow at Hannover Medical School (1996-98), before taking up an academicappointment at the University of Ulster in 1998. Promoted to Senior Lecturer and recipient of University of UlsterDistinguished Research Fellowship Award in 2001. Dr McClenaghan has over 110 peer-reviewed publications, hasbeen invited to speak at many national and international conferences. Patent holder, academic co-founder and ChiefOperating Officer of Diabetica Limted, a UU start-up company focused on innovative diabetes therapeutics.46
Main research interests:• Bioengineering pancreatic beta cells• stimulus-secretion coupling mechanisms• beta cell metabolism• ionic modulation of islet cell function• signal transduction pathways• apoptosis and mechanisms of beta cell demise and destruction• novel beta cell drug targets• actions of new insulinotropic antidiabetic agents• insulinotropic drug desensitization.Neville is Co-Founder, Stakeholder and Chief Operating Officer (COO) of spinout company Diabetica Limited,driving company development, operations and planning. He has managed an extensive patent portfolio and engagedwith corporate financiers, venture capital groups and major pharmaceutical and biotech companies for exploitationof novel IP, negotiating R&D and license agreements (~£23M to date). Neville is a named inventor, and author ofgrowing patent estate (comprising 11 national and international patents), has acted as consultant/advisor to numberof private and public sector clients and organizations, and is strongly committed to entrepreneurship, stimulation ofenterprise and creativity, wealth creation, and the knowledge-based economy.Neville has been recipient of a number of awards for research and academic enterprise activities and his primaryresearch interests are: bioengineering pancreatic islet cells; actions of anti-diabetic drugs and drug-induced beta-celldesensitization; tracing novel metabolic and beta-cell secretory pathways; and chronic detrimental beta-cell actionsof nutrients and the diabetic environment. Neville is author of over 50 published scientific papers; invited lecturer,chairperson/facilitator at numerous research and business conferences and meetings; and has regularly facilitatedpublic and private sector discussion and education on academic enterprise and in particular R&D for diabetes andobesity.Publications:Liu HK, McCluskey JT, McClenaghan NH, Flatt PR; Streptozotocin-resistant BRIN-BD11 cells possess a wide spectrumof toxin tolerance and enhanced insulin-secretory capacity; Endocrine, 32: 20-29, 2007Patterson S, Scullion SM, McCluskey JT, Flatt PR, McClenaghan NH; Prolonged exposure to homocysteine resultsin dimished but reversible pancreatic beta-cell responsiveness to insulinotropic agents. Diabetes Metab. Res. Rev.,23(4):324-334, 2007Liu HK, McCluskey JT, McClenaghan NH, Flatt PR; Iterative exposure of clonal BRIN-BD11 cells to ninhydrin enablesselection of robust toxin-resistant cells but with decreased gene expression of insulin secretory function; Pancreas,36: 294-301, 200847
Page 1: BIOMEDICAL SCIENCESRESEARCH INSTITU
Page 4 and 5: 1 Foreword by the Pro Vice-Chancell
Page 6 and 7: 2 Foreword by the Research Institut
Page 8 and 9: The BMSRI Research StructureThe BMS
Page 10 and 11: BMSRI Core FacilitiesContact: Karen
Page 12 and 13: of Metabolomics, pharmacy, nutritio
Page 14 and 15: BMSRI Academic Heads new Regional N
Page 16 and 17: 4. BIOMEDICAL GENOMICS RESEARCH GRO
Page 18 and 19: Recent Funding Initiatives:C-TRIC:
Page 20 and 21: Dr Mateus Webba da SilvaLecturer in
Page 22 and 23: 5. BIOIMAGING RESEARCH GROUPResearc
Page 24 and 25: developmental alterations that mani
Page 26 and 27: Publications:Bigot S, Lucas L, Morr
Page 28 and 29: Publications:Barnes CA, O’Hagan B
Page 30 and 31: We also measure the genotoxic effec
Page 32 and 33: 6. CANCER AND AGEING RESEARCH GROUP
Page 34 and 35: Professor Anthony P McHaleProfessor
Page 36 and 37: Professor Stephanie McKeownProfesso
Page 38 and 39: an Alzheimer Research Trust collabo
Page 40 and 41: JM, Waugh DJJ; Dexamethasone potent
Page 42 and 43: have wider applications in vivo, in
Page 44 and 45: Inter-relationships between diet an
Page 46 and 47: Flatt PR; Effective surgical treatm
Page 50 and 51: Dr YHA Abdel-WahabSenior Lecturer i
Page 52 and 53: Dr VA GaultLecturer in Molecular Bi
Page 54 and 55: McClean PL, Irwin N, Hunter K, Gaul
Page 56 and 57: Publications:Duffy NA, Green BD, Ir
Page 58 and 59: 8. MICROBIOLOGY AND BIOTECHNOLOGYRE
Page 60 and 61: Publications:Graham RJL, Graham C,
Page 62 and 63: analyses. However there is still a
Page 64 and 65: Plessas S, Bekatorou A, Koutinas AA
Page 66 and 67: Biochemical studies/ viral evasion
Page 68 and 69: Dr Stephen McCleanLecturer in Prote
Page 70 and 71: environmental remediation and as ro
Page 72 and 73: 9. NORTHERN IRELAND CENTRE FOR FOOD
Page 74 and 75: 26-28 Sept 2007: International Seaf
Page 76 and 77: Dr Barnes has developed expertise i
Page 78 and 79: Dr Alison GallagherSenior Lecturer
Page 80 and 81: In addition, results of a pilot stu
Page 82 and 83: Dr Maeve KerrResearch AssociateCont
Page 84 and 85: Memberships of External Committees/
Page 86 and 87: Indicators of Esteem:Professor McNu
Page 88 and 89: were examined. The intervention and
Page 90 and 91: Within this work both short-term an
Page 92 and 93: micronutrient supplementation at a
Page 94 and 95: 10. STEM CELL & EPIGENETICS RESEARC
Page 96 and 97: Publications:Lees-Murdock DJ, Lau H
Page 98 and 99:
Publications:Lees-Murdock DJ, Lau H
Page 100 and 101:
11. SYSTEMS BIOLOGY RESEARCH GROUPT
Page 102 and 103:
Kravtsov V, Swain M, Schuster A, Du
Page 104 and 105:
Dr Daniel BerrarLecturer in Biomedi
Page 106 and 107:
Zhang et al; Incorporating Feature
Page 108 and 109:
Bala P, Baldridge K, Benfenati E, C
Page 110 and 111:
In addition there is a growing them
Page 112 and 113:
Clinical work involves development
Page 114 and 115:
In 2009 he was appointed Chairman o
Page 116 and 117:
Stevenson TR, Goodall EA and Moore
Page 118 and 119:
Dr Raymond BeirneLecturer in Optome
Page 120 and 121:
Dr Julie McClellandLecturer in Opto
Page 122 and 123:
Graham JE, Moore JE, Moore JE, McCl
Page 124 and 125:
Research Staff:Dr David OrrSenior R
Page 126 and 127:
Dr Victoria McGilliganResearch Asso
Page 128 and 129:
13. Externally Funded Projects duri
Page 130 and 131:
Grant Holder Anderson, Prof RSFundi
Page 132 and 133:
Funding Body Royal Irish AcademyAmo
Page 134 and 135:
14. BIOMEDICAL SCIENCES RESEARCH IN
Page 136 and 137:
Student: Simon GenglerTitle: Effect
Page 138 and 139:
Student: Anisha MazumdarTitle: Anal
Page 140 and 141:
Student: Clare RyanTitle: How does
Page 142 and 143:
CONGRATULATIONS TO THE FOLLOWING PO
show all

biomedical sciences research institute - Research - University of Ulster

Create successful ePaper yourself

Delete template?

Save as template?